Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds

Zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination with daraxonrasib showed 81% objective response rate compared to zoldonrasib in combination with standard of care chemotherapy in previously untreated patients with RAS G12D metastatic pancreatic ductal adenocarcinoma, according to results of two phase I/II study.

July 10, 2026

Vol.52 No.27

Clinical Roundup

Tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells, UMiami study finds

A “tumor-on-a-chip” model is giving scientists a live look at how pancreatic cancer can recruit the body’s own immune cells to help tumors survive. The study reveals possible new targets to weaken the cancer’s defenses and make treatments work better.

July 10, 2026

Vol.52 No.27

In the Archives

Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise

When Robert Mayer was only a few years out of residency, in the 1970s, he signed on as an investigator of the NCI-supported Gastrointestinal Tumor Study Group, which conducted research into colorectal, gastric, and pancreatic cancers.

Dana-Farber names its under-construction freestanding hospital: the Lavine Bekenstein Cancer Hospital

Dana-Farber Cancer Institute announced the name of its 300-bed, freestanding cancer hospital, which is now under construction and will span 450,000 square feet across 10 inpatient floors: the Lavine Bekenstein Cancer Hospital. The building is expected to open in 2031.

June 26, 2026

Vol.52 No.25

In Brief

MD Anderson’s Vincent Bernard receives Project Purple’s Research Recovery Grant for pancreatic cancer research

Project Purple has awarded a $375,000 Research Recovery Grant to researchers at the University of Texas MD Anderson Cancer Center to continue critical pancreatic cancer research.

June 26, 2026

Vol.52 No.25

Clinical Roundup

TAMP procedure shows 52% reduction in pancreatic tumor metabolic activity, Moffitt case study shows

Researchers at Moffitt Cancer Center have published a case study highlighting the potential optimization of the TAMP, or trans-arterial micro-perfusion, procedure with RenovoCath to deliver intra-arterial gemcitabine (a commonly used chemotherapy) directly near a tumor (rather than traditional systemic IV administration) in a patient with locally advanced pancreatic cancer.

June 26, 2026

Vol.52 No.25

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS

PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

YOU MAY BE INTERESTED IN

Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds

Tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells, UMiami study finds

Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise

Dana-Farber names its under-construction freestanding hospital: the Lavine Bekenstein Cancer Hospital

MD Anderson’s Vincent Bernard receives Project Purple’s Research Recovery Grant for pancreatic cancer research

TAMP procedure shows 52% reduction in pancreatic tumor metabolic activity, Moffitt case study shows

Renew today!

Subscriber content

Never miss an issue!

Login